Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Schizophrenia is a devastating mental disorder characterized by relapsing psychotic episodes accompanied with emotional, professional and social decline. The classical dopamine hypothesis of schizophrenia postulates that hyperactivity of dopaminergic neurotransmission is responsible for the positive symptoms of the disorder, more exactly hyperactivity of the dopamine D2-like receptors. One of these receptors is the D4 receptor which is thought to be involved in the motor side-effects caused antipsychotics. However, research into the specific role of this receptor has been hampered by the lack of specific ligands. Therefore, a new 123I-labelled compound was developed which may allow in vivo visualization of the D4 receptor by SPECT. [123I]-3-(4-iodobenzyl)-1,2,3,4 -tetrahydro-8- hydroxychromeno[3,4-c]pyridin-5-one was prepared by electrophillic aromatic substitution of the tributylstannyl derivative. The radiochemical yield was 68 ± 3 % (n = 5) and the specific activity was > 2.96Ci/μmol. Copyright © 2005 John Wiley & Sons, Ltd.

Original publication




Journal article


Journal of Labelled Compounds and Radiopharmaceuticals

Publication Date





101 - 108